Bilgili Ahmet Mert, Durmaz Hacı Ömer, Dilber Muhammed
Medical Faculty Department of Otolaryngology, 64188Cyprus International University, Lefkoşe, Cyprus.
Odiology department, 420479Biruni University, İstanbul, Turkey.
Ear Nose Throat J. 2023 Jan;102(1):28-34. doi: 10.1177/01455613221123860. Epub 2022 Sep 2.
Adenoid hypertrophy (AH) is one of the common childhood diseases. Surgical and non-surgical treatment of AH in children is planned according to the severity of symptoms and associated complications. In recent years, treatment methods with intranasal sprays have been reported quite frequently in uncomplicated cases. We aim to evaluate the effectiveness of a new combination of azelastine - fluticasone (AZE-FLU) (137mcg azelastine and 50mcg fluticasone) nasal spray in children with uncomplicated AH.
Sixty-five children diagnosed with AH were included in the study. The mean age of the children was 7.42 ± 2.26 (4-13 years). The cohort consisted of 29 males and 36 females. All children were evaluated clinically and endoscopically. AZE-FLU nasal spray was applied to both nostrils twice a day for three months. Adenoid/choana ratio and symptom scores were evaluated before treatment and at the end of the 12th week.
At the end of 24 weeks of AZE-FLU application, there was a statistically significant decrease in both adenoid/choana ratio and symptom scores. While the initial adenoid/choana (A/C) score was 3.57 ± 0.58, it decreased to 1.74 ± 0.61 following treatment. A dramatic decrease in total symptom scores was observed. The total symptom score average was 15.63 ± 1.28 before treatment, while it was 2.31 ± 1.4 after the treatment with the difference being statistically significant ( < .01).
In this study, the effectiveness of AZE-FLU nasal spray on AH was investigated for the first time. This treatment provides an effective alternative to the surgical approach in children with uncomplicated adenoid hypertrophy. Using this protocol, 96% of patients were removed from the surgery list.
is IV.
腺样体肥大（AH）是儿童常见疾病之一。儿童AH的手术和非手术治疗是根据症状的严重程度及相关并发症来规划的。近年来，鼻喷雾剂治疗方法在无并发症的病例中报道较为频繁。我们旨在评估一种新的氮卓斯汀 - 氟替卡松（AZE - FLU）（137微克氮卓斯汀和50微克氟替卡松）鼻喷雾剂组合对无并发症AH儿童的有效性。
65名被诊断为AH的儿童纳入研究。儿童的平均年龄为7.42±2.26岁（4 - 13岁）。队列包括29名男性和36名女性。所有儿童均进行了临床和内镜评估。AZE - FLU鼻喷雾剂每天两次喷入双侧鼻孔，持续三个月。在治疗前和第12周结束时评估腺样体/后鼻孔比值和症状评分。
应用AZE - FLU 24周后，腺样体/后鼻孔比值和症状评分均有统计学意义的下降。初始腺样体/后鼻孔（A/C）评分为3.57±0.58，治疗后降至1.74±0.61。观察到总症状评分显著下降。治疗前总症状评分平均为15.63±1.28，治疗后为2.31±1.4，差异有统计学意义（P <.01）。
本研究首次调查了AZE - FLU鼻喷雾剂对AH的有效性。这种治疗为无并发症腺样体肥大儿童的手术治疗提供了一种有效的替代方法。采用该方案，96%的患者从手术名单中被剔除。
IV级
